Home › Trials › NCT02418442

Observational registry for children with rheumatic diseases

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Observational Duke University · NCT02418442

This study collects information from children with rheumatic diseases to help researchers understand how well different treatments work and keep everyone involved in the process.

Quick facts

Study typeObservational
Enrollment20000 (estimated)
AgesN/A to 21 Years
SexAll
SponsorDuke University Academic / other
Drugs / interventionsMethotrexate
Locations82 sites (Birmingham, Alabama and 81 other locations)
Trial IDNCT02418442 on ClinicalTrials.gov

What this trial studies

This observational registry continues the work of the CARRA Registry, which collects data on pediatric patients with rheumatic diseases to support future research. It aims to answer critical questions regarding the safety and effectiveness of various therapeutics used in treating these conditions. The registry engages families and communities to ensure comprehensive participation and data collection across multiple sites. The Duke Clinical Research Institute coordinates the registry, facilitating high-quality clinical and translational research.

Who should consider this trial

Good fit: Ideal candidates are children diagnosed with rheumatic diseases before the age of 16 for juvenile idiopathic arthritis or before 19 for other rheumatic diseases.

Not a fit: Patients over the age of 21 at the time of enrollment will not benefit from this study.

Why it matters

Potential benefit: If successful, this registry could enhance understanding of pediatric rheumatic diseases and improve treatment safety and efficacy.

How similar studies have performed: Other observational registries in pediatric rheumatology have shown success in advancing research and improving treatment outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
2. Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
3. Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.

Exclusion Criteria:

1\. Greater than 21 years of age at the time of enrollment.

Where this trial is running

Birmingham, Alabama and 81 other locations

+32 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Rheumatic Joint DiseaseSystemic ArthritisOligoarthritisPolyarthritisPsoriatic ArthritisEnthesitis Related ArthritisUndifferianted ArthritisCARRA Consensus Treatment Plans
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.